Rafael Holdings, Inc. (NYSE:RFL) Shares Shorted: Short Interest Down 55.9% in October

Rafael Holdings, Inc. (NYSE:RFL) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 348,361 shares, a decline of 55.9% from the September 30th total of 789,108 shares. Based on an average trading volume of 127,973 shares, the short-interest ratio is currently 2.7 days. Approximately 1.0% of the company’s shares are short sold.

Analyst Ratings Changes

Several equities research analysts have weighed in on RFL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Rafael in a research report on Tuesday, August 25th. Wall Street Zen upgraded shares of Rafael to a “hold” rating in a report on Saturday, July 25th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Rafael has an average rating of “Sell”.

Hedge Funds Weigh In On Rafael

A hedge fund recently bought a new position in Rafael stock. Kahn Brothers Group Inc. bought a new position in shares of Rafael Holdings, Inc. (NYSE:RFL) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 150,493 shares of the company’s stock, valued at approximately $494,000. Kahn Brothers Group Inc. owned 0.29% of Rafael as of its most recent filing with the Securities and Exchange Commission. 11.30% of the stock is owned by institutional investors.

Rafael Stock Performance

Shares of Rafael stock traded down $0.03 during midday trading on Friday, reaching $1.09. 67,242 shares of the company’s stock traded hands, compared to its average volume of 72,806. The stock has a 50 day moving average of $1.84 and a 200-day moving average of $1.69. Rafael has a 12 month low of $1.08 and a 12 month high of $3.96. The company has a market cap of $56.94 million, a PE ratio of -1.89 and a beta of 0.35.

Rafael (NYSE:RFL) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter. Rafael had a negative net margin of 3,390.73% and a negative return on equity of 39.52%. The company had revenue of $0.24 million for the quarter.

Rafael Company Profile

Rafael Holdings, Inc (NYSE:RFL) is a diversified holding company with interests in biotechnology and commercial real estate. Through its life sciences operations, the company has focused on developing potential treatments for cancer and other serious diseases, including therapies designed to target the metabolism of cancer cells.

Rafael’s biotechnology activities have been conducted primarily through Rafael Pharmaceuticals, which has researched investigational drug candidates such as devimistat (also known as CPI-613).